Omega Therapeutics Presents New Preclinical Data Supporting The Potential Of Precision Epigenomic Control At AACR 2024
Omega Therapeutics Presents New Preclinical Data Supporting The Potential Of Precision Epigenomic Control At AACR 2024
Omega Therapeutics 在 AACR 2024 上发布新的临床前数据，支持精准表观基因组控制的潜力
- MYC-directed epigenomic controller exerts anti-tumor effect in preclinical models of EGFR inhibitor-resistant NSCLC regardless of underlying resistance mechanism
- Validation of novel translational assay enables detection and quantification of site-specific DNA methylation from liquid biopsies to assess target engagement of OTX-2002, our lead clinical-stage epigenomic controller
- MYC 导向的表观基因组控制器在表皮生长因子抑制剂耐药性非小细胞肺癌的临床前模型中发挥抗肿瘤作用，无论潜在的耐药机制如何
- 对新型转化分析的验证可以检测和量化液体活检中的位点特异性 DNA 甲基化，以评估我们的主要临床阶段表观基因组控制器 OTX-2002 的靶标参与度